BioLamina and Spiber Technologies include exclusive agreements for the sale and marketing of unique BioSilk products

BioLamina AB has been selling reagents for 10 years to make it easier for customers to grow cells. The major trend right now in primary cell culture is to try to make more complex tissue models by culturing three-dimensional (3D) cells. Through collaboration and a licensing agreement with Stockholm's based Spiber Technologies AB, BioLamina can now offer a biorelevant way to grow cells in 3D.

BioLamina develops and sells high-quality products that support stem cell research, drug development and enables future cell therapies. BioLaminas products are used around the world today but have lacked tools for growing cells in 3D. After several years of collaboration with Spiber, Biolamina can now offer a unique product based on Spiber's recombinant silk protein combined with Biolaminins. Together, these proteins provide a 3D environment that can offer bio-relevance from biolaminins and 3D support from the silk.

BioLamina will launch the products at the international stem cell conference ISSCR in Los Angeles at the end of June. Soon after, the products will be available to customers worldwide.

"We are super excited about this new product! Everyone we have talked to about the product has said that this sounds much better than anything else on the market," says Kristian Tryggvason, CEO of BioLamina. "We think it is extremely fun to be able to offer this fantastic product developed in My Hedhammar's lab at KTH. They have done a fantastic job!"
My Hedhammar, Spiber's scientific co-founder continues, "It has been fun to cooperate with BioLamina and it is exciting to get our products out on the market after several years of development."

About BioLamina AB

BioLamina commercializes innovations that solve many of the technical problems that have hitherto made cell culture of embryonic stem cells and other primary cells difficult. Several of BioLamina's products are based on genetically engineered human recombinant proteins, called laminins. By covering surfaces used for cell culture with recombinant laminins, the natural environment of the body is imitated where these cells grow, which makes the cells thrive, expand and retain their function. This, in combination with some other innovations, solves several previous problems associated with primary cell cultures such as reliability and low cell quality and enables clinical development of new cell therapies.

For more information:

About Spiber Technologies AB

Spiber Technologies AB is a research-intensive biotech company based in Stockholm. Spiber develops, produces and commercializes products based on recombinant spider proteins. Main application areas are in medical technology, primarily cell culture, incl. stem cells, and regenerative medicine.


For more information, please contact:

BioLamina AB

Kristian Tryggvason


Phone: +46 8 5888 5181